Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568202 · ClinicalTrials.gov registry record
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
A clinical trial of Congenital Bleeding Disorder and Haemophilia B, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 449
- Enrollment target
- 1
- Study location
NCT02568202: Completed study of Congenital Bleeding Disorder and Haemophilia B, sponsored by Novo Nordisk A/S.
NCT02568202 is a study of Congenital Bleeding Disorder and Haemophilia B that has completed, run by Novo Nordisk A/S. The registered enrollment target is 449 participants, above the 83-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (441% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02568202, a study of Congenital Bleeding Disorder and Haemophilia B, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 449 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is conducted in the United States of America (USA). Tha aim of this study is bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S).
Conditions Studied
Interventions
- OTHER No treatment given
Study Locations (1)
New Jersey
- Novo Nordisk Clinical Trial Call Center - Plainsboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-11 |
What the finished NCT02568202 record still lists
NCT02568202 is an observational study that tracks outcomes without assigning an intervention. The registered 449 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (441% higher).
The record links to 3 conditions, with Congenital Bleeding Disorder appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.
NCT02568202 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02568202 about?
NCT02568202 is a clinical study titled "Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)". This study is conducted in the United States of America (USA). Tha aim of this study is bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S).
What is the current status of trial NCT02568202?
This trial is currently completed. The enrollment target is 449 participants. The study started on 2015-09. Estimated completion is 2015-11.
What conditions does trial NCT02568202 study?
This clinical trial studies the following conditions: Congenital Bleeding Disorder, Haemophilia B, Haemostasis.
What interventions are being tested in trial NCT02568202?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT02568202?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02568202 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Bleeding Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02568202's enrollment target sits among peer trials
449 1st of 8 higher than 8 of 8 other Congenital Bleeding Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Bleeding Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
COMPLETED · Phase 2
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
COMPLETED · Phase 3
-
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
COMPLETED · Phase 3
-
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia